Floatz logo

CINREBAFUSP ALFA

Urinary Bladder Cancer

Pieris Pharmaceuticals, Inc.monoclonal_antibodyPhase 1Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Urinary Bladder Cancer cohort.

Asset / SponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Atezolizumab
National Cancer Institute (NCI)
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2BB
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 2BB
Carboplatin
Iambic Therapeutics, Inc
Phase 2BB

View all 45 →

Same molecule, other indications

CINREBAFUSP ALFA is also rated in:

HER2-positive Solid TumorDormant
CCC
Indicative ·
52 / 100
View asset →
gastric cancerDormant
CCC
Indicative ·
50 / 100
View asset →
HER2 positive breast carcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →